The emergence of a wider range of treatment options in multiple myeloma, including newer immunotherapies, has improved outcomes, notably for patients with relapsed or refractory disease.
Nurses play a pivotal role in the successful use of these therapies by providing in-depth patient education about methods of administration and wide-ranging side effects. Considering the multiple options now available, and their complexity and varied safety profiles, it is important for nurses to understand the newer immunotherapies to prepare patients adequately for shared decision-making.
Oncology nurse practitioner Charise Gleason from Emory Winship Cancer Institute discusses the latest advances in immunotherapy for relapsed/refractory multiple myeloma patients, ways in which these therapies affect nursing care, and how nurses can prepare to incorporate them smoothly into clinical practice.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Immunotherapy in Relapsed/Refractory Multiple Myeloma: Nursing Considerations - Medscape - Jun 21, 2022.
Comments